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A comprehensive meningococcal vaccine is yet to be developed. In the absence of a vaccine that
immunizes against the serogroup B capsular polysaccharide, this can only be achieved by
targeting subcapsular antigens, and a number of outer-membrane proteins (OMPs) are under
consideration as candidates. A major obstacle to the development of such a vaccine is the
antigenic diversity of these OMPs, and obtaining population data that accurately identify and
catalogue these variants is an important component of vaccine design. The recently proposed
meningococcal molecular strain-typing scheme indexes the diversity of two OMPs, PorA and
FetA, that are vaccine candidates, as well as the capsule and multilocus sequence type. This
scheme was employed to survey 323 meningococci isolated from invasive disease in England and
Wales from 1975 to 1995, before the introduction of meningococcal conjugated serogroup C
polysaccharide vaccines in 1999. The eight-locus typing scheme provided high typeability
(99.4%) and discrimination (Simpson’s diversity index 0.94–0.99). The data showed cycling of
meningococcal genotypes and antigenic types in the absence of planned interventions.
Notwithstanding high genetic and antigenic diversity, most of the isolates belonged to one of
seven clonal complexes, with 11 predominant strain types. Combinations of PorA and FetA,
chosen on the basis of their prevalence over time, generated vaccine recipes that included protein
variants found in 80% or more of the disease isolates for this time period. If adequate immune
responses can be generated, these results suggest that control of meningococcal disease
with relatively simple protein component vaccines may be possible.
INTRODUCTION
The lack of a comprehensive vaccine for protection against
meningococcal disease has been highlighted by the devel-
opment and introduction of conjugate polysaccharide
vaccines against serogroups A, C, Y and W-135 (Jodar
et al., 2002). Serogroup B, the predominant cause of
meningococcal disease in many countries (Caugant, 1998),
is not, therefore, covered by routine immunization and
the development of a conjugate vaccine against this
polysaccharide is hampered by low immunogeniticy and
perceived safety issues (Stein et al.,2 0 0 6 ) .B o t ht h e s e
problems are a consequence of the identity of this molecule
with host polysaccharides (Finne et al.,1 9 8 3 ) .V a r i o u s
approaches that use subcapsular antigens, both proteins and
polysaccharides, have been proposed to provide what are
best described as serogroup B substitute meningococcal
vaccines (Jodar et al.,2 0 0 2 ) .
Any meningococcal vaccine must accommodate the
extensive genetic and antigenic diversity of this common
inhabitant of the human nasopharynx (Stephens, 2007).
Two contrasting approaches have been employed: the
identification of conserved antigens; or the generation of
specific vaccines against certain types. The former includes
the identification of candidate antigens from genome
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type; VR, variable region.
3Present address: Department of Medical Microbiology, University of
Maastricht, Maastricht, The Netherlands.
Microbiology (2008), 154, 1170–1177 DOI 10.1099/mic.0.2007/014761-0
1170 2007/014761 G 2008 SGM Printed in Great Britainsequence data, so-called reverse vaccinology (Pizza et al.,
2000), while the latter is exemplified by the use of outer-
membrane vesicle (OMV) vaccines to disrupt outbreaks of
serogroup B disease caused by a single meningococcal
clone (Bjune et al., 1991; O’Hallahan et al., 2004; Sierra
et al., 1991). In practice the identification of highly
conserved antigens has proved difficult, probably because
any surface component that is expressed at sufficient levels
to be a vaccine target is naturally variable. There remains
the possibility of either making specific vaccines that target
particular meningococcal variants or producing multiva-
lent formulations of antigens that achieve broad coverage
(van den Dobbelsteen et al., 2007). Both these approaches
require detailed information about the molecular epidemi-
ology of the meningococcus (Perrett & Pollard, 2005).
Despite their high diversity, meningococcal populations are
structured into lineages that are identified as clonal
complexes (cc) by multilocus sequence typing (MLST)
(Maiden et al., 1998). Only a minority of these, the so-
called hyperinvasive lineages, are regularly associated with
human disease (Caugant, 2001; Maiden et al., 1998;
Yazdankhah et al., 2004). The prevalence of these lineages
varies geographically and temporally but each complex
tends to be associated with a particular repertoire of surface
antigens (Urwin et al., 2004). Three strain-specific vaccines,
based on OMV preparations, have been developed and
deployed in response to particular outbreaks of meningo-
coccal disease (Oster et al., 2005; Perkins et al., 1998). A
more general approach is to identify combinations of
meningococcal surface protein variants that will protect
against all or at least a high proportion of meningococcal
disease; however, the success of such vaccines will depend
on the stability of association of antigen variants with
invasive meningococci over time (Sacchi et al., 2000).
In the present work, molecular typing, based on the
nucleotide sequence determination of meningococcal genes
(Elias et al., 2006; Jolley et al., 2007), was employed to
identify the variants of two major surface proteins, PorA
and FetA, in England and Wales over 20 years prior to the
introduction of meningococcal serogroup C conjugate
(MCC) vaccines (Miller et al., 2001). These proteins are
both typing targets and components that have been present
in a number of strain-specific meningococcal vaccines
(Jodar et al., 2002). In addition, the clonal complex and
hence the hyperinvasive lineage was determined by MLST
(Maiden et al., 1998). The data produced a highly
discriminatory typing scheme but, notwithstanding a very
high diversity of strain types, a relatively simple vaccine
based on combinations of PorA and FetA variants could
potentially protect against a majority of meningococcal
disease over this extended period of time.
METHODS
Bacterial isolates. A total of 125 isolates had been stored from 1975,
comprising all of the isolates submitted to the Health Protection
Agency England (HPA, formerly Public Health Laboratory Service
England and Wales, PHLS) central reference laboratory in 1975.
Although they did not necessarily provide a representative sample of
the disease at that time, this is one of the largest isolate collections,
with accompanying documentation, for one country from that time.
By 1985 the more systematic submission of isolates to the HPA (at
that time PHLS, England and Wales) Meningococcal Reference Unit
(MRU) was common and a subset of 100 representative isolates
was chosen from these. For 1995, when the MRU received nearly all
meningococci isolated from notified cases of invasive disease, a
structured sample was generated by choosing every tenth isolate
submitted for inclusion in the survey, up to a total of 100 isolates.
This gave a total of 325 stored isolates included in the study, which
were cultured on heated-blood agar plates overnight. A total of 323 of
these isolate were cultivatable: two of the 1975 isolates failed to grow.
The overnight growth was used to prepare DNA using an Isoquick
extraction kit (Orca Research). Sequence type (ST) information was
gained from the two non-viable isolates by extraction of DNA from
the stored material.
MLST. This was performed as described previously (Jolley et al.,
2000). Briefly, the seven housekeeping loci used in the scheme were
amplified by PCR and the amplicons purified by precipitation to
remove unincorporated amplification primers and nucleotides. These
were then used as templates for dideoxynucleotide sequence reactions
using BigDye Terminators (ABI). The extension reactions were
separated on an automated DNA analyser (ABI) and the sequences
assembled with the Staden software package (Staden, 1996).
Antigen gene sequencing. The nucleotide sequence determination
of the regions of the porA gene that encode most of the antigenic
variability of this protein, VR1 and VR2, was undertaken using
previously published methods (Suker et al., 1994). The region of the
FetA gene that encodes the principal variable region (VR) of this
protein was similarly determined (Thompson et al., 2003). For both
proteins the peptide sequences were deduced and assigned names
using the published nomenclature schemes (Jolley et al., 2007; Russell
et al., 2004; Thompson et al., 2003).
Data storage and analysis. Data were stored on a customized
isolate database available at http://pubmlst.org/neisseria/. The data-
base automatically generated the strain types according to the recently
proposed typing nomenclature (Jolley et al., 2007). This has the
format serogroup:PorA type:FetA type:sequence type (clonal
complex); for example B:P1.7-2,4:F1-5:ST-41 (cc41/44). Analysis
was conducted with the PubMLST database tools (Jolley & Maiden,
2006; Jolley et al., 2004). The diversity index for strain types was
calculated according to Simpson (1949) and modified for strain
typing (Hunter & Gaston, 1988).
RESULTS
Diversity of strain types
Serogroup information was available for 313 (96%) of the
meningococci examined and complete molecular char-
acterization for MLST, porA and fetA loci for 323 (99%)
isolates. The two incompletely characterized isolates were
the non-viable isolates from the 1975 sample; these were
excluded from further analysis. A total of 204 unique strain
types were present among the 323 isolates, providing
diversity indices of 0.94 for the 1975 isolates and 0.99 for
the 1985 and 1995 isolate collections. With the exception of
serogroup, of which only four were present in each
collection, the isolate collection from 1975 was less diverse
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measured (Table 1). The complete dataset, including
geographical distribution of isolates, is available at http://
pubmlst.org/neisseria.
Prevalence of serogroups and clonal complexes
over time
Most isolates were serogroup B (71% of isolates in 1975,
67% of isolates in 1985, and 58% of isolates in 1995), with
serogroup C the next most prevalent, rising from 20% of
isolates in 1975 through 27% of isolates in 1985, to 36% of
isolates in 1995. Serogroup A represented 10% of the
isolates in 1975 and 2% in 1985: it was not present in the
1995 sample. Most serogroup W-135 isolates were present
in 1975 (6.5% of isolates) and most serogroup Y in 1985
(4% of isolates).
Each serogroup was mainly associated with particular
clonal complexes in a given year, but this changed over
time (Table 2). There were differences in the clonal
complexes present in each of the three years, and the
disappearance of serogroup A disease from the UK over the
duration of the survey was due to the disappearance of
members of the ST-1 complex. Serogroup A is mostly
found in members of the ST-1, ST-4 and ST-5 complexes,
which rarely express capsules of other serogroups, and their
disappearance from most industrialized countries over the
period of the survey is yet to be satisfactorily explained
(Achtman, 1997). In contrast, the serogroups expressed by
other clonal complexes changed during this period. For
example, the percentage of isolates that were serogroup C
increased from 20% to 36% but whereas most of these
isolates belonged to ST-344 complex in 1975, the ST-11
complex was the major cause of serogroup C disease in
1995; members in this clonal complex predominantly
expressed serogroup W-135 in 1975. In 1975 most
serogroup B meningococcal disease was caused by ST-8
isolates; this was succeeded by members of the ST-32
complex in 1985 and members of the ST-41/44 complex in
1995 (Table 2).
Prevalence of strain types over time
A total of 12 (5%) of the strain types were observed five
times or more in the isolate collection, accounting for 93
(30%) of all isolates. Of the remaining strain types, 168
(82%) were observed only once (48/125 in 1975, 51/100 in
1985, and 68/100 in 1995) and 15 (7%) types were
observed twice: two in 1975 and 1985 [B:P1.7,16-2:F1-
5:ST-32 (cc32) and B:P1.7-2,13-1:F3-9:ST-8 (cc8)] and
two in 1985 and 1995 [B:P1.19,15:F5-1:ST-34 (cc32) and
C:P1.5,2:F5-8:ST-11 (cc11)]. Of the eight strain types
observed three times (4%), only one occurred in two years
[B:P1.19-1,15-11:F1-7:ST-269 (cc269) in 1985 and 1995)]
and both (1%) of the types observed four times (2%) were
limited to one year. Together with isolates belonging to the
same clonal complex, the most prevalent strain types
accounted for between 76% and 88% of the disease
isolates in any one year, although the prevalence of strain
types varied with time (Table 3).
Table 1. Diversity of meningococci isolated from invasive
disease over 20 years in England and Wales
Number
1975 1985 1995
Isolates 125 100 100
Sequence typed 123 100 100
Strain types 67 70 79
Serogroups 4 4 4
PorA VR1 variants 15 18 13*
PorA VR2 variants 20 25 21
FetA VR variants 23 19 22
STs 48 55 52
Clonal complexes 13 18 11
Isolates not assigned to a complex 4 5 6
*Including one isolate with a stop codon in VR1.
Table 2. Association of serogroups with predominant clonal complexes over time
Clonal complex Prevalence (%)
1975 1985 1995
A B C W-135 A B C W-135 A B C W-135
ST-1 complex 9.2 2
ST-8 complex 38 4 6 2 6
ST-11 complex 0.8 4.9 7 4 27
ST-32 complex 0.8 31 7
ST-41/44 complex 5.7 11 1 25 1
ST-334 complex 2.4 16 3 4
ST-269 complex 0.8 7 12
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There were 131 unique combinations of PorA VR1, PorA
VR2 and FetA VR, including three isolates that could not be
characterized for PorA. Of the remaining 128 combinations,
85 occurred only once. Of the 43 combinations observed
more than once, 30 were only seen in one year, ten in two
years and three in all three years. The two most frequent
combinations in the whole dataset were each observed in
onlyone year: P1.5-1,2-2:F3-6, which was presentin 27% of
the 1975 isolates, and P1.7-2,4:F1-5, which was present in
8.9% of the 1995 isolates. The most prevalent PorA VR1
variantwas7-2,themostprevalentPorAVR2variantwas2-2
and the most prevalent FetA VR was F1-5 (Table 4). The
combined prevalence of the five most common variants was
68% for PorA VR1, 48% for PorA VR2, and 66% for FetA
VR. There were a limited number of combinations of the
different VRs in the dataset with a tendency for non-
overlapping structure (Gupta et al., 1996), although this was
more marked with the two PorA VRs than with the PorA
VRs and FetA VR (Fig. 1). The data permitted the design of a
possible combination of PorA and FetA VRs for use in a
vaccine, and the assessment of possible levels of coverage that
such a vaccine might be able to attain, in the absence of
immunological constraints (Fig. 2).
DISCUSSION
Public health interventions against variable pathogenic
bacteria require accurate, portable and reproducible typing
schemes. This is especially important if, as with the
meningococcus, the bacterium is not an obligate pathogen
because the identification of invasive types can affect the
nature of the intervention deployed (Maiden, 2002, 2004).
MLST has provided a very reliable means of identifying
hyperinvasive meningococci (Brehony et al., 2007), but
does not necessarily provide sufficient discrimination for
the unambiguous identification of disease clusters repre-
senting outbreaks (Bygraves et al., 1999; Feavers et al.,
1999). The addition of PorA and FetA VRs added
discrimination and identified antigen variants in this
sample of invasive meningococci (Jolley et al., 2007) and
such ‘fine typing’ has been employed in the identification
of outbreak clusters in Germany (Elias et al., 2006).
The levels of discrimination achieved in the current survey
were high (Simpson’s diversity index 0.94–0.99), compar-
able with the result achieved with PorA and FetA typing
previously, 0.96 (Elias et al., 2006). They were also similar
to the best levels of coverage and precision achieved with
other methods, indicating that the nine-gene sequence
typing scheme has sufficient discrimination for the reliable
detection of outbreaks (Swaminathan et al., 1996). In
addition, the clonal complex information identified
hyperinvasive lineages, enabling the monitoring of trends
Table 3. Prevalence of strain types represented more than five
times and strain types belonging to the same clonal complex
Strain type Prevalence (%)
1975 1985 1995 Mean
ST-8 complex
B:P1.5-1,2-2:F3-6:ST-8 (cc8) 24 8.1
B:P1.19,15:F3-9:ST-8 (cc8) 3.3 1 1.4
23 other cc8 strain types 12 9 8 9.7
ST-41/44 complex
B:P1.7-2,4:F1-5:ST-41 (cc41/44) 3 6 3
40 other cc41/44 strain types 6.5 9 22 10
ST-11 complex
C:P1.5,2-1:F5-5:ST-11 (cc11) 6 2 2.7
C:P1.5,2:F3-6:ST-11 (cc11) 6 2
C:P1.5-1,10-4:F3-6:ST-11 (cc11) 6 2
21 other cc11 strain types 5.7 1 18 8.7
ST-32 complex
B:P1.19,15:F5-1:ST-33 (cc32) 6 1 2.3
B:P1.7,16-2:F1-5:ST-74 (cc32) 4 2 2
B:P1.7,16-2:F1-5:ST-343 (cc32) 5 1.7
15 other cc32 strain types 0.8 16 5 7.3
ST-1 complex
A:P1.5-2,10:F5-1:ST-1 (cc1) 4 1 2
5 other cc1 strain types 5.7 1 2.7
ST-334 complex
C:P1.5-1,2-2:F1-5:ST-334 (cc334) 3.3 1 1.7
23 other cc334 strain types 15.5 6 8.3
ST-269 complex
B:P1.19-1,15-11:F5-1:ST-269 (cc269) 3 1
13 other cc269 isolates 0.8 4 12 5.6
Total 82.1 76 88 82
Table 4. Most prevalent protein antigen variants
Rank order Protein variant (prevalence in all three years, %)
PorA VR1 PorA VR2 FetA VR
1 5-1 (23.4) 2-2 (15.2) F1-5 (23.8)
2 5 (13.1) 2 (11.1) F3-6 (15.6)
3 7-2 (12.4) 4 (8) F5-1 (11.7)
4 7 (9.6) 15 (7.6) F3-9 (9.8)
5 19 (9.6) 10 (6.4) F4-1 (4.8)
Combined prevalence 68.1 48.3 65.7
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other datasets (Brehony et al., 2007). Furthermore, as the
procedure is PCR based it is inherently suitable for
application to clinical specimens (Taha et al., 2005), and
finally, the typing data were also informative as to the
antigenic variability of the meningococcus.
The lower estimate of diversity index from the 1975 dataset
was probably due to the limitations in geographical
sampling of disease isolates at this time. Most of the
isolates present in the collections for the two later years
were independent. However, as the 1975 sample was the
complete set of isolates available from submissions to the
PHLS, it is possible that epidemiologically related isolates
were present, which could also explain the high proportion
of ST-8 isolates; indeed it is perhaps more likely that
outbreak isolates would have been submitted to the PHLS
reference facilities at this time. Geographical source of
Fig. 1. Prevalence of PorA and FetA VR
variants from 1975 to 1995. (a) The number of
isolates with particular PorA VR1 and VR2
combinations. (b) The number of isolates with
particular PorA VR2 and FetA VR combinations.
J. E. Russell and others
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and for 93 of the 1985 isolates. Of the 48 locations that
submitted isolates in 1975, 12 submitted four or more with
the greatest (Manchester) submitting 20. By contrast, in
the 1985 dataset 55 locations were represented, only two
of which (London, eight and Manchester, four) were
represented more than three times. Similarly, in the 1995
dataset of 67 locations, only London and Manchester (five
isolates each) were represented by more than three isolates.
The data were consistent with previous studies that have
indicated dynamic behaviour in meningococcal popula-
tions (Caugant, 2001; Harrison et al., 2006; Yazdankhah
et al., 2004). Disease incidence rises and falls with the
presence of hyperinvasive lineages in the carried popu-
lation of meningococci. The antigens associated with
particular clonal complexes consequently rise and fall over
time, as predicted by models of pathogen strain structuring
by immunological selection (Gupta & Maiden, 2001),
although there appeared to be differences in the stability of
the lineages with regard to different antigens. The ST-1
clonal complex is very strongly associated with particular
antigenic variants, including capsule and subcapsular
antigens (Suker et al., 1994; Urwin et al., 2004), and
serogroup A disease disappeared from the UK with this
clonal complex. Despite reintroduction since then, for
example with ST-5 complex meningococci in the 1990s,
serogroup A meningococci have not, to date, re-established
themselves as a cause of disease in the UK (Jones &
Sutcliffe, 1990). The sialic-acid-based capsules, corres-
ponding to serogroups B, C, Y and W-135, have a more
dynamic relationship with clonal complex. This may reflect
the fact that horizontal gene exchange of only the gene
occupying the siaD locus of the capsular region is required
to alter the serogroup (Swartley et al., 1997; Vogel et al.,
2000). A further difference is that the serogroup A capsule
is thought to be more immunogenic (Gold et al., 1979).
The clonal complexes associated with capsules containing
sialic acid (the ST-8, ST-32, ST-344 and ST-41/44
complexes) are, however, more limited in the repertoire
of subcapsular antigens that they express, each being
associated with particular variant families. In particular,
there was a tendency of the VRs to occur in non-
overlapping combinations (Fig. 1), which, along with the
dynamic behaviour noted above, is consistent with models
of strain structuring based on herd immunity (Gupta &
Maiden, 2001; Gupta et al., 1996). This also confirmed the
observations made on a global dataset, where it was
suggested that combinations of PorA VRs and FetA VRs
might be an effective means of controlling meningococcal
disease (Urwin et al., 2004). Simple vaccines based on
combinations of these two components could achieve
high coverage of circulating meningococci (Fig. 2). The
implementation of such a vaccine may require epidemio-
logical monitoring to ensure that it remains effective
(Trotter et al., 2007).
Current approaches in the development of a comprehens-
ive meningococcal vaccine can be divided into two distinct
strategies: those seeking to enhance the immune response
to conserved antigens and those based on highly immuno-
genic yet variable antigens. While not excluding the utility
of vaccines based on conserved antigens, the observations
reported here support the development of multivalent
formulations consisting of variable antigens. The evidence
of strain structuring indicates that such antigens are
the principal targets of natural immunity. This is also
consistent with clinical studies of OMV vaccines, which
have repeatedly highlighted the importance of PorA for
vaccine-induced immunity. In terms of clinical devel-
opment, the most advanced multivalent vaccines consist of
OMVs produced from genetically modified strains expres-
sing multiple variants of PorA (van den Dobbelsteen et al.,
2007). The present study provides a rational approach for
deciding which variants should be included in this type of
vaccine. It further suggests that ensuring the expression of
appropriate variants of a second antigen, such as FetA,
would be an effective way of broadening vaccine coverage.
In conclusion, meningococci isolated from cases of invasive
disease are highly diverse at both housekeeping protein and
antigen encoding loci; however, much of this diversity is
transient, especially the minor variants of protein antigens.
A more limited repertoire of antigen variants is persistent
over time and these tend to be associated with particular
invasive lineages. Combinations of subcapsular antigens
reappear over time, sometimes associated with different
lineages, perhaps in response to increases and decreases of
herd immunity against particular strain types. This leads to
the possibility that appropriately composed component
vaccines may be able to protect human populations from
meningococcal disease over periods of time sufficient to
warrant their development and implementation.
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